Are you an investigator looking to learn more about Candel’s clinical trials? New and registered users can use the sign-up and login forms below.
Are you treating NSCLC patients who may be interested in clinical trial participation? We are actively enrolling across multiple U.S. centers to a Phase 2 clinical trial for patients with NSCLC who have suboptimal response (either stable disease or disease progression) on first line anti-PD-(L)1 inhibitor therapy. Learn more by clicking this link.
Registered users can also request to be contacted by a Candel team member to learn more about this clinical trial and opportunities for your patients to participate.